Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) comprises a heterogenous group of lymphoid tissue tumours, distinguished from Hodgkin’s lymphoma by their absence of Reed-Sternberg cells on ...


Read more on Non-Hodgkin lymphoma

 

Latest news articles

Added 17 days ago Drug news

Complete response letter for BLA for biosimilar rituximab.- Sandoz.

Sandoz, a Novartis division, announced that the FDA has issued a complete response letter (CRL) regarding the Biologics Licensing Application...

Added 18 days ago Drug news

FDA approves Kymriah for large B-cell lymphoma as second indication for CAR-T therapy.- Novartis.

The FDA has approved Kymriah (tisagenlecleucel) suspension, from Novartis, for intravenous infusion for its second indication - the treatment of...

Added 1 month ago Drug news

FDA gives priority review for IPI 145 in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.- Verastem.

Verastem announced that the FDA has accepted for filing with Priority Review its New Drug Application (NDA) for its lead...

Search all news articles for Non-Hodgkin lymphoma
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Load more

Guidelines

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations...

Added 3 years ago

Guidelines on the investigation and management of follicular lymphoma

The objective of this guideline is to provide healthcare professionals with clear guidance on the management of patients with follicular lymphoma.

Added 6 years ago

ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 1 year ago

Search all guidelines for Non-Hodgkin lymphoma
 

Journal articles

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.

Added 3 months ago

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder comprising about 6-10% of all B cell lymphoma cases. Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), a key component of early B-cell receptor (BCR) signalling pathways.

Added 3 months ago

Systematic review of infectious events with the BTK inhibitor ibrutinib in the treatment of haematologic malignancies.

Objective: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B-lymphocytes as well as other kinases including interleukin-2-inducible T-cell kinase (ITK) in CD4+ Th2 regulatory T-cells.

Added 3 months ago

Search all journal articles for Non-Hodgkin lymphoma
 

Clinical trials

A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma...

Added 11 months ago

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

The primary objective of the the trial is to establish one of three study arms...

Added 1 year ago

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator...

Added 11 months ago

Search all clinical trials for Non-Hodgkin lymphoma
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Night sweats - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0
Search all CME for Non-Hodgkin lymphoma